baricitinib mg mg gain approv slight posit read-
abbvi
approv lower-dos option mg olumi baricitinib treatment
moder sever rheumatoid arthriti ra patient inadequ
respons one tumor necrosi factor inhibitor tnfi higher dose
mg approv label includ black box warn risk
friday june partner announc fda
seriou infect malign thrombosi decis approv
mg dose larg expect given doubt rais april advisori committe
adcom meet vote support mg dose mg
dose base question safeti signal includ imbal sever cardiovascular
cv event mostli associ higher dose howev note
restrict patient fail least one tnfi came bit surpris
sinc compani origin appli mg olumi use methotrex
inadequ respond dose demonstr good efficaci patient
popul although believ approv posit overal narrower-than-
expect label like reduc olumi competit market opinion
note baricitinib first next-gener trifecta jak inhibitor
reach approv two follow upadacitinib gilead
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
compani note olumi launch unit state end second quarter price
discount lead tnf inhibitor estim olumi cost annual per patient
previou estim discount note narrow label restrict
lower dose may limit market share olumi among next-gener jak inhibitor result fda
approv label decis decreas fair valu estim share base
follow chang model increas probabl olumi commerci
also stand receiv million mileston compani expect recogn second quarter
howev note due approv mg dose data demonstr superior mg olumi
humira well radiograph respons data associ higher dose includ label togeth
label restrict tnfi-inadequ respond believ limit overal hinder competit
market uptak result decreas peak penetr estim olumi base
chang well lower-than-expect price forecast peak world-wide olumi revenu billion
previou estim billion note stand receiv tier royalti olumi sale
rang partner decreas sale consequ reduc estim peak revenu incyt
million million result fair valu decreas share
view olumi approv slight net posit upadacitinib next-gener jak inhibitor
upadacitinib wrap expans phase program ra expect file nda later efficaci
side believ upadacitinib demonstr potenc advantag olumi mg safeti side
upadacitinib mg olumi roughli equival similar uncertainti also associ upadacitinib
sever cv event overal believ olumi approv benefici sinc decis reflect
agenc recept novel agent address area high unmet need despit question safeti base
clearer trial design data date continu view upadacitinib path approv potenti
greater commerci competit base efficaci potenti approv patient beyond tnfi-inadequ
respond current model peak sale upadacitinib ra billion
olumi approv indic black box warn togeth creat restrict label first-
gener jak inhibitor xeljanz believ could limit uptak market
despit seemingli better efficaci note xeljanz approv use inadequ respond
olumi limit later line therapi failur least one tnfi although cross-trial comparison suggest
olumi might efficaci xeljanz believ restrict address popul
decreas market competit xeljanz also carri black box warn seriou infect
malign note class effect jak inhibitor therapi inclus thrombosi
addit warn olumi label set apart xeljanz safeti side also like
contribut limit accept among physician opinion
part approv compani agre perform random control clinic trial
evalu long-term safeti olumi ra patient could also slow launch dynam
view due rare occurr advers event interest thrombosi causal link
olumi could definit rule adcom discuss sinc clinic studi
design power seriou natur possibl associ
jak inhibit mechan fda requir random control clinic studi continu explor
potenti causal well expand safeti databas avail mg dose olumi note
expect post-market studi conduct given four adcom panel member vote favor
approv mg dose specif suggest post-market studi necessari comment howev
requir control trial rather observ studi came bit surpris believ
physician begin prescrib olumi soon enter market other might like
wait robust safeti databas built prescrib olumi higher cv-risk patient
could slow initi uptak view
approv mg dose olumi restrict tnfi-inadequ respond also leav
room upcom competit line upadacitinib compani expect file
nda later year base data date believ upadacitinib demonstr highest potenc
comparison xeljanz baricitinib particularli indic upadacitinib may produc best rate
deep earli respons across tnfi-inadequ respond safeti side base data
abbvi phase ra program far believ safeti concern plagu olumi may less
issu evalu upadacitinib nda potenti support stronger risk/benefit profil date four
five abbvi phase ra program studi read report venou thromboembol event
proportion-adjust ratio upadacitinib versu placebo still numer imbalanc note
overal rate event consist background rate ra popul believ
smaller differenti upadacitinib placebo could start allevi safeti concern regard
mechan jak inhibit addit safeti efficaci databas upadacitinib evenli balanc
across two dose studi provid clearer interpret result similar baricitinib upadacitinib
evalu two differ dose mg qd mg qd trial begin
placebo/act compar phase follow crossov upadacitinib howev case upadactinib
studi placebo patient roll ratio dose upadacitinib result even
accumul patient exposur time dose efficaci safeti comparison requir
dose upadacitinib baricitinib well-balanc patient exposur databas provid
stronger power mg qd mg qd straightforward analysi result opinion
togeth potenti stronger efficaci believ total upadacitinib data could strengthen
risk/benefit profil upadacitinib posit prefer agent class potenti reach
maintain market perform rate lower fair valu estim share base
rational describ exhibit probability-adjust net present valu npv model assign per
share jakafi per share iclusig per share olumi previous ad per share net
cash year-end arriv fair valu assess share
upcom catalyst includ data jakafi phase ii pivot studi steroid-refractori acut
gvhd first half initi pivot trial jakafi essenti thrombocythemia epacadostat keytruda nsclc
rcc scchn bladder cancer itacitinib gvhd b-cell malign dose escal data
fgfr brd pim inhibitor pair biopsi data in-hous combo inhibitor
risk market perform rate includ clinic risk pipelin unforeseen competit
jakafi competit olumi
drugpeak salesstag developmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair marketedapprov nov marketedapprov juli eu market tier present valu addit william blair estimatessum-of-part fair valu exhibit corporationfair valuenet year-end import disclosur
william blair affili market maker secur incyt corpor abbvi inc
william blair affili expect receiv intend seek compens invest bank servic incyt corpor
abbvi inc affili within next three month
offic employe william blair affili research analyst may financi interest secur
corpor abbvi inc
report avail electron form regist user via doc http //williamblairlibrari bluematrix com
pleas contact us consult williamblair com/research-and-insights/equity-research/coverag aspx disclosur
katherin xu attest view express research report accur reflect his/her person view
secur compani cover report part his/her compens relat directli indirectli
specif recommend view express him/her report seek updat research appropri
certain period industri report major report publish irregular interv deem appropri research
incyt corpor rate histori
power bluematrix
op outperform market market perform perform nr rate initi coverag drop coverag
abbvi inc rate histori
power bluematrix
op outperform market market perform perform nr rate initi coverag drop coverag
current rate distribut june
